ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sanofi, Lunan Pharmaceutical Group and Boehringer Ingelheim side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Sanofi×Lunan Pharmaceutical Group×Boehringer Ingelheim×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SanofiLunan Pharmaceutical GroupBoehringer Ingelheim
studies on the registry2,425392,305
open to participants now1041961
phase 3 studies under way611028
reach primary completion within a year64445
programswith a study of their own in two years80+12 named only2045+21 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSanofiLunan Pharmaceutical GroupBoehringer Ingelheim
Phase 128%

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 1

  1. F182112phase 1
  2. LNF2007phase 1
  3. LNF2105phase 1
  4. Dronedaroneno phase
  5. Budesonideno phase

and 3 more — sign in to see them all

40%

Boehringer Ingelheim: 18 of its 45 programs at phase 1

  1. BI 3821001phase 1
  2. BI 3000202_low dosephase 1
  3. BI 3776528phase 1
  4. BI 3810944phase 1
  5. BI 3814916phase 1

and 13 more — sign in to see them all

40%
Phase 2

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%

Lunan Pharmaceutical Group: 4 of its 20 programs at phase 2

  1. F182112+CD38phase 2
  2. mosapridephase 2
  3. Vonorasan fumarate injection1phase 2
  4. Vonorasan fumarate injection2phase 2
20%

Boehringer Ingelheim: 15 of its 45 programs at phase 2

  1. BI 3034701phase 2
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2
  3. BI 1584862phase 2
  4. BI 1815368phase 2
  5. BI 3000202phase 2

and 10 more — sign in to see them all

33%
Phase 3

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 3

  1. rulonilimabphase 3
  2. Beclomethasonephase 3
  3. Cetirizinephase 3
  4. Diphenhydraminephase 3
  5. F027phase 3

and 3 more — sign in to see them all

40%

Boehringer Ingelheim: 9 of its 45 programs at phase 3

  1. obrixtamigphase 3
  2. survodutidephase 3
  3. nerandomilastphase 3
  4. verducatibphase 3
  5. zongertinibphase 3

and 4 more — sign in to see them all

20%
Approved, new studies

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%
00%

Boehringer Ingelheim: 3 of its 45 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Tenecteplaseapproved, new study
  3. Pramipexoleapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Lunan Pharmaceutical Group4 readouts · 1 phase 3·

Lunan Pharmaceutical Group, Dec ’26: 1 program whose next study reaches primary completion

  1. LNF2007phase 1 · Dec 0 · NCT06752447
·

Lunan Pharmaceutical Group, Feb ’27: 2 programs whose next study reaches primary completion

  1. Vonorasan fumarate injection1phase 2 · Feb 0 · NCT06783257
  2. Vonorasan fumarate injection2phase 2 · Feb 0 · NCT06783257
···

Lunan Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Isosorbidephase 3 · Jun 30 · NCT06765993
····
Boehringer Ingelheim20 readouts · 3 phase 3·

Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3

  1. survodutidephase 3 · Dec 8 · NCT07768813
  2. zongertinibphase 3 · Dec 10 · NCT06151574
  3. empagliflozinapproved, new study · Dec 11 · NCT07845630
  4. vicadrostatphase 3 · Dec 11 · NCT07845630
  5. verducatibphase 3 · Dec 14 · NCT07781631

and 3 more — sign in to see them all

·

Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion

  1. BI 3776528phase 1 · Feb 3 · NCT06745297

Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion

  1. BI 764524phase 2 · Mar 5 · NCT06321302
  2. ezabenlimabphase 3 · Mar 8 · NCT05846516
  3. BI 765423phase 2 · Mar 11 · NCT07036523
  4. BI 3812465phase 2 · Mar 23 · NCT07553429

Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. nerandomilastphase 3 · Apr 15 · NCT06806592
·

Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion

  1. BI 3821001phase 1 · Jun 22 · NCT07908004

Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion

  1. BI 3814916phase 1 · Jul 12 · NCT07486115
  2. BI 3032950phase 2 · Jul 30 · NCT06636656

Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion

  1. BI 3802876phase 2 · Aug 5 · NCT07325526
  2. Anti-SIRPa Monoclonal Antibody BI 770371phase 2 · Aug 31 · NCT06806852
·

Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Tenecteplaseapproved, new study · Oct 2 · NCT07361302
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Lunan Pharmaceutical Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Boehringer Ingelheim

New programs 3

  • BI 4015092phase 1 · first study · Nov 3
  • BI 3968621phase 1 · first study · Sep 25
  • pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis

Study stopped 0

None

Primary completion later 7

Where they overlap

Conditions where at least two of them have programs: 24 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionSanofiLunan Pharmaceutical GroupBoehringer Ingelheim
Carcinoma, Non-Small-Cell Lungall three · compare here

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Lunan Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. rulonilimabphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Boehringer Ingelheim in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. zongertinibphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2

Their studies: Boehringer Ingelheim’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2all three · compare here

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Lunan Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. F027phase 3
  2. Valsartanphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Boehringer Ingelheim in Diabetes Mellitus, Type 2: 3 programs

  1. survodutidephase 3
  2. vicadrostatphase 3
  3. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 2 in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

Lunan Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

Boehringer Ingelheim in Pulmonary Disease, Chronic Obstructive: 1 program

  1. verducatibphase 3

Their studies: Boehringer Ingelheim’s studies of Pulmonary Disease, Chronic Obstructive in search

Colitis, Ulcerativeall three · compare here

Sanofi in Colitis, Ulcerative: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Colitis, Ulcerative in search

Lunan Pharmaceutical Group in Colitis, Ulcerative: 1 program

  1. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colitis, Ulcerative in search

Boehringer Ingelheim in Colitis, Ulcerative: 1 program

  1. BI 3032950phase 2

Their studies: Boehringer Ingelheim’s studies of Colitis, Ulcerative in search

Colorectal Neoplasmsall three · compare here

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Lunan Pharmaceutical Group in Colorectal Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Boehringer Ingelheim in Colorectal Neoplasms: 3 programs

  1. ezabenlimabphase 3
  2. pumitamigphase 2
  3. Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049phase 1

Their studies: Boehringer Ingelheim’s studies of Colorectal Neoplasms in search

Lupus Erythematosus, Systemicall three · compare here

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

Lunan Pharmaceutical Group in Lupus Erythematosus, Systemic: 1 program

  1. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Lupus Erythematosus, Systemic in search

Boehringer Ingelheim in Lupus Erythematosus, Systemic: 1 program

  1. BI 3000202phase 2

Their studies: Boehringer Ingelheim’s studies of Lupus Erythematosus, Systemic in search

Asthma2 of 3 · compare here

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

Lunan Pharmaceutical Group in Asthma: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Asthma in search

–
Small Cell Lung Carcinoma2 of 3 · compare here–

Lunan Pharmaceutical Group in Small Cell Lung Carcinoma: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Small Cell Lung Carcinoma in search

Boehringer Ingelheim in Small Cell Lung Carcinoma: 5 programs

  1. obrixtamigphase 3
  2. ezabenlimabphase 3
  3. Etoposidephase 3
  4. pumitamigphase 2
  5. Zocilurtatug Pelitecanphase 2

Their studies: Boehringer Ingelheim’s studies of Small Cell Lung Carcinoma in search

Diabetes Mellitus, Type 12 of 3 · compare here

Sanofi in Diabetes Mellitus, Type 1: 4 programs

  1. frexalimabphase 3
  2. brivekimigphase 2
  3. Biological Productsphase 1
  4. teplizumabapproved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 1 in search

–

Boehringer Ingelheim in Diabetes Mellitus, Type 1: 1 program

  1. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Diabetes Mellitus, Type 1 in search

COVID-192 of 3 · compare here

Sanofi in COVID-19: 3 programs

  1. NVX-COV2705phase 3
  2. Biological Productsphase 1
  3. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study

Their studies: Sanofi’s studies of COVID-19 in search

–

Boehringer Ingelheim in COVID-19: 1 program

  1. apecotrepphase 3

Their studies: Boehringer Ingelheim’s studies of COVID-19 in search

Heart Failure2 of 3 · compare here–

Lunan Pharmaceutical Group in Heart Failure: 2 programs

  1. Valsartanphase 3
  2. Dronedaroneno phase

Their studies: Lunan Pharmaceutical Group’s studies of Heart Failure in search

Boehringer Ingelheim in Heart Failure: 2 programs

  1. vicadrostatphase 3
  2. empagliflozinapproved, new study

Their studies: Boehringer Ingelheim’s studies of Heart Failure in search

Multiple Myeloma2 of 3 · compare here

Sanofi in Multiple Myeloma: 1 program

  1. Anti-GPRC5D Monoclonal Antibody SAR446523phase 1

Their studies: Sanofi’s studies of Multiple Myeloma in search

Lunan Pharmaceutical Group in Multiple Myeloma: 3 programs

  1. F182112 single-agentphase 3
  2. F182112+CD38phase 2
  3. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Multiple Myeloma in search

–

Show all 24

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Sanofi 53 of 80 · Lunan Pharmaceutical Group 8 of 20 · Boehringer Ingelheim 24 of 45 programs (27 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12, Boehringer Ingelheim: 21).